



<http://researchspace.auckland.ac.nz>

## ***ResearchSpace@Auckland***

### **Copyright Statement**

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

### **General copyright and disclaimer**

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the [Library Thesis Consent Form](#) and [Deposit Licence](#).

### **Note : Masters Theses**

The digital copy of a masters thesis is as submitted for examination and contains no corrections. The print copy, usually available in the University Library, may contain corrections made by hand, which have been requested by the supervisor.

***Staphylococcus aureus* population genetics  
and immune responses: correlation with  
ethnic variation in the incidence of  
bacteraemia**

Stephen Robert Ritchie

A thesis submitted in fulfilment of the requirements for the degree of  
Doctor of Philosophy in Molecular Medicine and Pathology, The  
University of Auckland, 2010.

I dedicate this work to my late friend Professor Peter Black. Peter always encouraged me to pursue an interest in research and was always excited to hear about progress and offer advice. I miss the enlightening conversations we had in the hallways around the hospital and the medical school.

# Acknowledgement

I was fortunate to have the benefit of three supervisors during this PhD study.

Professor John Fraser provided oversight of the study of the sera and his kind and thoughtful encouragement and insights always helped rapidly resolve problems that arose.

Professor Paul Rainey supervised the analysis of the population genetic data, and his enthusiasm, intelligence and patience was required to help me up the huge learning curve required for this aspect of the study.

Associate-Professor Mark Thomas provided general oversight of the PhD programme and mentored me throughout the process. He listened to me and solved any problems that arose and managed to maintain my focus when things didn't go to plan. It is a great privilege to be able to work with Mark and to continue to benefit from his education, advice and friendship.

A number of other people helped me with this project. Drs David Holland, Selwyn Lang and Susan Taylor helped me to access patients and specimens at Middlemore Hospital. At LabPLUS, Dr Sally Roberts, Maree Gillies, Mary Bilkey and Tracy Bathgate helped me obtain bacterial strains and with phenotypic testing; and Pat Lonsdale helped me to obtain serum samples. Dr Arthur Morris provided data from Diagnostic-Medlab.

Dr Craig Thornley and Dr Ron King [from the Auckland Regional Public Health Service] provided advice regarding data collection and analysis. Dr Alistair Stewart provided statistical advice and Professor Marti Anderson, provided advice regarding the comparison of bacterial populations. Ms Nicola Best helped with collection of nasal swab specimens during a summer studentship. Dr Graeme Lindsay proof read the thesis and provided impeccable advice.

James Alesana-Slater and his supervisor Professor Pauline Norris collaborated with the collection of SA strains in Samoa; James recruited the patients and performed the swabs in Samoa. Helen Heffernan at ESR performed *spa* typing and pulsed-field gel electrophoresis on selected isolates. Mary Fakahau sent me SA isolates from Tonga and Eka Buadromo helped me to arrange ethical approval to obtain isolates in Fiji, she also provided me with access to her lab in Suva to package the isolates to be sent back to Auckland.

In John Fraser's lab, Dr Fiona Radcliffe, Dr Ries Langley, Dr Amanda Taylor, Dr Nicola Jackson and Dr Matthew Chung all spent time teaching me mysterious laboratory methods. Fiona Clow managed project funding and tirelessly answered my numerous questions.

In Paul Rainey's lab, Dr Xue-Xian Zhang helped me to trouble shoot issues with PCR and Dr Eric Libby provided advice and explanation regarding mathematical aspects of population genetics.

My colleagues in the Infectious Disease department at Auckland City Hospital tolerated my absence from the roster and helped out with my clinic patients when I wasn't around.

This work was supported financially by the Health Research Council of New Zealand and the University of Auckland. I owe gratitude to the many cases of staphylococcal disease and their families who were willing to meet with me and talk to me, despite the horrendous illness they were experiencing at the time.

I owe special thanks and gratitude to my family, whose unwavering love and support was provided unconditionally. My children, Ben, Rosie and Ed never complained when I was grumpy or frequently absent; all of you constantly amaze me and I promise to make it up to you! My wife provided support and helped in too many ways to list; Katie, I love you and thank you for allowing me to indulge my aspirations.

# Abstract

**Introduction:** *Staphylococcus aureus* [SA] is a common cause of disease in New Zealand, in particular the incidence of SA bacteraemia [SAB] is high. SAB is more common in Māori and Pacific people than people of other ethnicities, but the reasons for this discrepancy are not known.

**Aim:** This thesis investigated a range of reasons for ethnic variation in the incidence of SA infections in Auckland. In particular, the genetic structure of SA populations in Auckland, Samoa, Fiji and Tonga were determined and the adaptive immune responses to SA toxins were determined.

**Materials and Methods:** 150 cases of SAB were interviewed and provided serum samples for analysis. 424 healthy population members were interviewed and cultures were performed of nasal swab specimens. Multi-locus sequence typing was performed on SA isolates from 150 cases of SAB in Auckland, 94 healthy nasal carriers in Auckland, 96 people with skin and soft tissue infection in Samoa, 109 people with predominantly skin and soft tissue infection in Fiji and 18 people with a variety of diseases in Tonga. Radioimmunoassay was used to measure antibody concentrations against toxic shock syndrome toxin [TSST-1] and four staphylococcal superantigen-like proteins [SSL] in acute and convalescent sera from 148 cases of SAB and sera from 21 healthy population members.

**Results:** The incidence of SAB was higher in Māori and Pacific people, but was not caused by a higher prevalence of nasal colonisation or infection with different, more virulent strains of SA. The SA populations in Auckland, Samoa and Fiji were not substantially different; furthermore, the SA populations in the Pacific were not substantially different to SA populations in other parts of the world. Indicators of socioeconomic deprivation were more common in cases of SAB, but Māori and Pacific cases of SAB reported similar access to healthcare as cases of other ethnicities. Sera from Māori and Pacific SAB cases had lower concentrations of neutralising antibody against TSST-1 and SSL9 compared with sera from SAB cases of other ethnicities.

**Conclusion:** Ethnic variation in the incidence of SAB is multi-factorial; socioeconomic deprivation, increased rates of illness requiring invasive medical devices and adaptive immune responses all contribute.

# Contents

<b>Acknowledgement</b> .....	<b>iii</b>
<b>Abstract</b> .....	<b>v</b>
<b>Contents</b> .....	<b>vi</b>
<b>FOREWORD</b> .....	<b>1</b>
<b>PART A: CLINICAL STUDIES INVESTIGATING THE SPECTRUM OF SA DISEASE IN AUCKLAND AND THE PACIFIC</b> .....	<b>4</b>
<b>Chapter 1: Ethnic variation in the incidence of Staphylococcus aureus bacteraemia in Auckland</b> .....	<b>4</b>
1.1 Introduction.....	4
1.2 Materials and Methods .....	6
1.2.1 Selection of cases of SAB .....	6
1.2.2 Clinical review .....	6
1.2.3 Methods of analysis and definitions used .....	7
1.2.4 Statistical methods .....	9
1.3 Results .....	11
1.3.1 Age, gender and ethnicity of cases of SAB .....	11
1.3.2 The education level, personal income and occupation of cases of SAB.....	14
1.3.3 The deprivation index of the neighbourhood of domicile of SAB cases .....	15
1.3.4 Alcohol usage and cigarette smoking .....	16
1.3.5 The household characteristics of cases of SAB .....	16
1.3.6 Access to healthcare.....	17
1.3.7 Past history of infection caused by SA and comorbid illness .....	17
1.3.8 Past History of infection caused by SA.....	18
1.3.9 Acquisition of SA infection .....	18
1.3.10 The cause of SAB: diagnosis and MRSA .....	19
1.3.11 Disease severity and length of hospital stay .....	20
1.3.12 The outcome and mortality of SAB .....	20
1.3.13 Comparison of indicators of deprivation with population values .....	22
1.3.14 Summary of ethnic variation among cases of SAB .....	22
1.3.15 The difference between ethnic groups after stratification by age .....	24
1.3.16 The incidence of SAB adjusted for the presence of renal disease and diabetes .....	24
1.3.17 Factors associated with community-onset SAB .....	25
1.4 Discussion.....	26
<b>Chapter 2: The burden of <i>S. aureus</i> skin and soft tissue infection in Auckland and evidence of ethnic variation between subtypes of methicillin-resistant <i>S. aureus</i> causing wound infection in Auckland</b> .....	<b>29</b>
2.1 Introduction.....	29
2.2 Materials and Methods .....	31
2.3 Results .....	32
2.3.1 The prevalence and susceptibility of MRSA in Auckland .....	32
2.3.2 MRSA subtype and age .....	32
2.3.3 The difference in MRSA subtype by ethnic group .....	34
2.3.4 The incidence of nm-MRSA and mr-MRSA infection .....	35
2.4 Discussion.....	37

<b>Chapter 3: The prevalence and diversity of MRSA causing wound infection in Samoa.....</b>	<b>39</b>
3.1 Introduction.....	39
3.2 Aims .....	40
3.3 Materials and Methods .....	41
3.3.1 Study procedure.....	41
3.3.2 Microbiological methods .....	41
3.4 Results .....	43
3.5 Discussion .....	47
<b>Chapter 4: The prevalence and demographic features of <i>S. aureus</i> carriage in Auckland .</b>	<b>49</b>
4.1 Introduction.....	49
4.1.1 Immune and genetic differences between persistent carriers and persistent non-carriers .....	50
4.1.2 Bacterial determinants of nasal colonisation .....	50
4.1.3 Demographic variation in nasal colonisation .....	51
4.2 Materials and Methods .....	52
4.2.1 Study participants .....	52
4.2.2 Culture of SA.....	52
4.2.3 Analysis.....	53
4.3 Results .....	54
4.3.1 SA nasal carriage.....	55
4.3.2 Deprivation and household crowding.....	55
4.3.3 Recent healthcare exposure.....	56
4.4 Discussion.....	57
<b>PART B: POPULATION GENETICS OF <i>STAPHYLOCOCCUS AUREUS</i> .....</b>	<b>59</b>
<b>Chapter 5: The genetic structure of <i>Staphylococcus aureus</i> populations from the Pacific and comparison with the rest of the world .....</b>	<b>59</b>
5.1 Introduction.....	59
5.1.1 Multi-locus sequence typing [MLST]: comparison of invasive disease isolates and nasal carriage isolates in Oxford .....	60
5.1.2 Differences in invasive SA isolates and nasal carriage isolates of SA.....	61
5.1.3 The global population structure of SA.....	61
5.1.4 Population genetic study of <i>S. aureus</i> .....	63
5.1.5 Mutation, random genetic drift and phylogenies of SA .....	63
5.1.6 Recombination .....	67
5.1.7 Selection pressure .....	68
5.1.8 Migration .....	69
5.1.9 Estimating the adequacy of the sample.....	72
5.2 Aims .....	74
5.3 Materials and Methods .....	75
5.3.1 Identification and testing of SA isolated from nasal swabs.....	75
5.3.2 Selection of SA colonies for genotypic testing.....	77
5.3.3. Genomic DNA preparation.....	77
5.3.4 Polymerase chain reaction [PCR] and PCR primer design .....	77
5.3.5 Sequence manipulation .....	80
5.3.6 Novel SA strains .....	80
5.3.7 Software and parameter settings.....	81
5.3.8 The global dataset of SA MLST sequences .....	84
5.4 Results .....	86
5.4.1 The population structure of <i>S. aureus</i> that caused bacteraemia and asymptomatic nasal colonisation in Auckland during 2007.....	86
5.4.1.1 The strains of SA isolated from people with bacteraemia .....	86
5.4.1.2 The strains of SA isolated from people with asymptomatic nasal colonisation....	86
5.4.1.3 Polymorphism within the Auckland sample of SA .....	87
5.4.1.4 Identification of a genetic outgroup of SA that caused nasal colonisation .....	88
5.4.1.5 The Auckland sample of SA is a comprehensive representation of the total SA population in Auckland .....	89



5.4.1.6 The sample of SA in Auckland would not have improved with additional sampling .....	90
5.4.1.7 The rates of recombination and point mutation of SA isolated from people living in Auckland .....	90
5.4.1.8 Recombination was detected in nucleotide sequences of housekeeping genes of SA .....	90
5.4.1.9 Recombination in the nucleotide sequence alignment of SA has occurred between housekeeping genes .....	92
5.4.1.10 SA has lower rates of recombination than <i>Streptococcus pneumoniae</i> and <i>Neisseria meningitidis</i> .....	92
5.4.1.11 The sequence types of SA in Auckland.....	93
5.4.1.12 The Auckland SA population lacks genetic diversity compared with outlier strains .....	95
5.4.1.13 The ancestry of the Auckland SA sample: analysis of ST alleles .....	96
5.4.1.14 The ancestry of the Auckland SA sample: phylogeny derived from nucleotide sequences .....	97
5.4.1.15 The ancestry of the Auckland SA sample: the ancestral source of nucleotide polymorphism .....	99
5.4.1.16 Evidence of SA evolution in New Zealand .....	101
5.4.1.17 The influence of selection on housekeeping genes of SA .....	103
5.4.1.18 Migration: evidence of transmission of novel sequence types .....	103
5.4.1.19 Comparison of the sequence types that cause nasal colonisation and bloodstream infection .....	103
5.4.1.20 Testing the null hypothesis of no difference between the blood and nasal groups of SA .....	104
5.4.1.21 SA lineage that causes infection in Māori and Pacific people in Auckland .....	106
5.4.1.22 Further resolution of STs within CC30 by PFGE did not provide additional correlation with ethnic group or methicillin resistance .....	108
5.4.1.23 The analysis of genes in addition to the conventional housekeeping genes does not add to the ability of MLST to differentiate strains of SA .....	110
5.4.1.24 The functional importance of <i>ssl7</i> codons under selection pressure .....	110
5.4.1.25 Co-evolution of <i>ssl7</i> with SA housekeeping genes .....	111
5.4.2 Comparison of the genetic structure of SA populations in Auckland, Samoa, Fiji and Tonga .....	113
5.4.2.1 The sample of SA strains from Samoa.....	113
5.4.2.2 The sample of SA strains from Fiji .....	113
5.4.2.3 The sample of SA strains from Tonga.....	114
5.4.2.4 The SA samples from Samoa and Fiji were representative of the total SA population in each country.....	114
5.4.2.5 The STs of SA that cause infection in Samoa and Fiji were similar.....	116
5.4.2.6 Differences in abundant STs that cause infection in Fiji, Samoa or Auckland... ..	117
5.4.2.7 The Phylogeny of SA in the Pacific .....	120
5.4.2.8 Limited evidence of geographical clustering within the phylogeny of SA in the Pacific .....	120
5.4.2.9 ST93, ST96 and CC121 cause infection only in Māori and/or Pacific people....	123
5.4.2.10 Minimal difference in the population structure of SA that infect people living in Pacific Island nations or that infect people living in Auckland .....	124
5.4.2.11 No difference in the diversity of the SA population in different Pacific nations	125
5.4.2.12 Statistically significant differences between the genetic structure of SA populations from different Pacific nations.....	126
5.4.2.13 Significant differences in the genetic structure of SA populations from different Pacific nations were caused by minimal differences between populations.....	126
5.4.2.14 Novel SA strains in Pacific Island nations with small human populations.....	128
5.4.2.15 Migration of novel STs in the Pacific .....	130
5.4.3 Migration and evolution of SA in the global SA population .....	130
5.4.3.1 Geographical variation and evolution in SA phylogeny .....	130
5.4.3.2 Differences between SA populations from Pacific island nations and Mali.....	132
5.4.3.3 Geographically diverse SA populations are similar .....	132
5.4.3.4 No difference between the SA population in Pacific countries and the SA population in Mali.....	134

5.4.3.5 Estimating the Molecular clock rate of SA.....	135
5.4.3.6 The SA population is young and the effective population size of SA has increased recently .....	138
5.4.3.7 The origins of CC75 outlier strains and time of divergence .....	140
5.5 Discussion .....	144
5.5.1 The SA population in Auckland.....	144
5.5.1.1 Origin of novel STs in Auckland .....	144
5.5.1.2 No difference between blood and nasal SA populations in Auckland .....	145
5.5.1.3 Difference in SA STs in different ethnic groups .....	145
5.5.2 Comparison of the Auckland SA population with SA populations in Fiji, Samoa and Tonga .....	146
5.5.2.1 Difference between the frequencies of predominant STs in Pacific countries... ..	146
5.5.2.2 The SA populations in neighbouring Pacific Island nations are similar .....	148
5.5.2.3 CC121 strains are common in the Pacific .....	148
5.5.2.4 Evolutionary relationships derived from point mutation identified divergent SA strains in Auckland and Fiji.....	148
5.5.3 The global SA population - novel STs are common .....	149
5.5.3.1 Geographically diverse SA populations are similar .....	150
5.5.4 A model of SA evolution and dispersal .....	150
5.5.4.1 The ancestral phase of SA evolution.....	151
5.5.4.2 The isolation phase of SA evolution .....	151
5.5.4.3 The bottleneck phase of SA evolution.....	153
5.5.4.4 The rapid migration phase of SA evolution .....	154
5.5.4.5 Alternative models of SA evolution.....	155
5.6 Summary.....	156

**PART C: HUMAN IMMUNE RESPONSES TO STAPHYLOCOCCAL TOXIC SHOCK SYNDROME TOXIN, AND STAPHYLOCOCCAL SUPERANTIGEN-LIKE PROTEINS 3, 7, 9 AND 11..... 157**

**Chapter 6: Demographic variation in the immune responses to staphylococcal toxic shock syndrome toxin and lack of neutralisation of specific anti-SSL7 antibody..... 157**

6.1 Introduction.....	157
6.1.1 Are effective vaccines against SA available? .....	158
6.1.2 Vaccination against staphylococcal alpha toxin did not reduce SA infection in high-risk patients.....	158
6.1.3 Vaccination against the SA polysaccharide capsule did not reduce SAB .....	159
6.1.4 Do immune responses to infection protect against SA infection? .....	159
6.1.5 People who are immune-suppressed are at increased risk of SA infection .....	159
6.1.6 Differences between persistent non-carriers and persistent carriers of SA .....	159
6.1.7 Prior colonisation increases the risk of SA disease, but protects against death from SAB.....	160
6.1.8 Antibodies against SA antigens are ubiquitous in adults and develop in infancy.....	160
6.1.9 Does immunity to TSST-1 prevent disease? .....	161
6.1.10 TSST-1 is a potent superantigen .....	161
6.1.11 Low anti-TSST-1 antibody levels were more common in people who developed TSS .....	161
6.1.12 The role of TSST-1 in SAB .....	162
6.1.13 Staphylococcal superantigen-like proteins .....	162
6.1.14 The function of SSL7 .....	163
6.1.15 Immune responses to SSL7 .....	164
6.1.16 The function of SSL9 .....	164
6.1.17 The function of SSL3 and SSL11 .....	164
6.2 Aims .....	165
6.3 Materials and Methods.....	166
6.3.1 Serum samples.....	166
6.3.2 Storage of serum .....	166
6.3.3 Recombinant SSL proteins .....	166
6.3.4 Expression of recombinant protein .....	167

6.3.5 Purification of recombinant SSL7 alleles .....	168
6.3.6 Purification of recombinant TSST-1 .....	168
6.3.7 Radio-labelling of recombinant proteins .....	168
6.3.8 Preparation of Cowan I <i>S. aureus</i> cells as a protein A source .....	169
6.3.9 Radioimmunoassay for antibodies to staphylococcal toxins .....	169
6.3.10 Preparation of PBMCs for a T cell proliferation assay .....	171
6.3.11 T cell proliferation assay .....	171
6.3.12 Functional anti-TSST-1 antibody assay .....	172
6.3.13 ELISA of SSL7 binding to complement factor C5 in human serum .....	172
6.3.14 Detecting anti-SSL7 antibodies that reduce binding of SSL7 to complement factor C5 .....	173
6.3.15 SSL7 alternative pathway complement inhibition assay .....	175
6.3.16 Assay for anti-SSL7 antibodies that neutralise SSL7 inhibition of complement mediated haemolysis .....	176
6.4 Results .....	178
6.4.1 Convalescent serum .....	179
6.4.2 Antibodies against TSST-1 .....	180
6.4.3 No increase in anti-TSST-1 antibody level after bacteraemia .....	180
6.4.4 A high proportion of people with bacteraemia have antibodies that inhibit the function of TSST-1 .....	181
6.4.5 The concentration of anti-TSST-1 antibody correlates with neutralisation of TSST-1 function .....	183
6.4.6 Anti-SSL7 antibodies are ubiquitous in adults .....	184
6.4.7 No important difference between anti-SSL7 antibody concentrations in acute and convalescent sera .....	185
6.4.8 No difference in anti-SSL7 antibody values between different alleles of SSL7 .....	186
6.4.9 Anti-SSL7 antibodies that block the binding of SSL7 to C5 are uncommon .....	187
6.4.10 Anti-SSL7 antibodies that neutralise SSL7 mediated inhibition of haemolysis are uncommon .....	188
6.4.11 Anti-SSL3 antibodies are ubiquitous in adults .....	190
6.4.12 Anti-SSL9 antibodies are ubiquitous in adults .....	191
6.4.13 A small proportion of adults lack anti-SSL11 antibodies .....	192
6.4.14 Seroconversion to SSL11 does occur during SAB .....	193
6.4.15 Radioimmunoassay for anti-SSL5 antibodies .....	194
6.4.16 Correlation between anti-TSST-1 antibodies and anti- SSL3, SSL7, SSL9 and SSL11 antibodies .....	195
6.4.17 No correlation between anti-SSL antibodies and the age of cases of SAB .....	195
6.4.18 Gender has no effect on the development of antibodies to staphylococcal toxins ..	196
6.4.19 Ethnic variation in anti-TSST-1 antibody and anti-SSL9 antibody .....	196
6.4.20 No effect of deprivation on antibodies against staphylococcal toxins .....	199
6.4.21 Antibodies against staphylococcal toxins do not prevent death caused by SAB ...	200
6.4.22 Other demographic factors were not associated with differences in antibodies against staphylococcal toxins .....	200
6.5 Discussion .....	201
6.5.1 Immune responses to SSL proteins .....	201
6.5.2 Antibodies against TSST-1 correlate with neutralisation of TSST-1 function .....	201
6.5.3 Antibodies against SSL7 were ubiquitous but antibodies the blocked binding of SSL7 to C5 were rare .....	202
6.5.4 Selection pressure in <i>ss/7</i> and lack of allelic variation in anti-SSL7 antibodies .....	205
6.5.5 Anti-SSL3 antibodies were increased during SAB .....	206
6.5.6 The limitations of radio-immunoassay for anti-SSL5 antibodies .....	206
6.5.7 Ethnic variation in anti-TSST-1 and anti-SSL9 antibody concentrations .....	206
6.5.8 Summary .....	207
<b>Chapter 7: Conclusion and future directions .....</b>	<b>208</b>
7.1 The prevalence of nasal colonisation might be higher in Māori and Pacific people .....	208
7.2 Colonisation with particularly virulent strains of SA might be more frequent in Māori and Pacific people .....	208
7.3 The use of invasive devices, which increase the risk of invasion by colonising organisms, might be higher in Māori and Pacific people .....	209

7.4 Innate or adaptive immune responses against SA might be less protective against invasive disease.....	209
7.5 Māori and Pacific people might develop mild SA disease that might be neglected or undertreated and progress to SAB .....	210
7.6 Ethnic variation in rates of SAB might be caused by increased susceptibility and exposure to SA due to socioeconomic deprivation.....	210
7.7 Questions for future research .....	211
<b>Appendix A: Example of population genetic analysis using ssl11 gene fragment .....</b>	<b>215</b>
A.1 Example of calculation of the genetic distance between nucleotide sequences .....	215
A.2 Example rarefaction curve.....	216
A.4 Example of Efron's calculation and Simpson's index of diversity .....	217
A.5 Example of estimation of recombination and mutation: LDHAT .....	218
A.6 Example of detecting recombination .....	219
A.7 Example of finding recombination breakpoints using GARD .....	219
A.8 Example of estimating selection pressure for nucleotide sequences .....	220
A.9 Example of the parsimony test and LibShuff.....	221
A.10 Example of 2 dimensional multi-dimensional scaling.....	223
A.11 Example of ANOSIM and PERMANOVA .....	224
A.12 Example of phylogeny reconstruction using maximum likelihood: TREEPUZZLE ....	226
A.13 Example of ancestral population using STRUCTURE .....	227
<b>Appendix B: Forms used for data collection.....</b>	<b>229</b>
B.1 Consent form .....	229
B.2 Participant information sheet.....	231
B.3 Data collection for cases of SAB .....	235
B.4 Revised consent form for carriage study.....	237
B.5 Revised participant information sheet for carriage study .....	238
B.6 Carriage study data collection form.....	240
<b>References cited .....</b>	<b>241</b>